Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Annexin V and Apoptosis After Myocardial Infarction

    2026-11-03

    What does an Annexin V apoptosis assay actually establish after myocardial infarction? The central question is narrower than whether a treatment has improved cardiac repair: does it change the population of cells displaying phosphatidylserine on the external plasma-membrane surface? Annexin V binds exposed phosphatidylserine, a membrane-state change commonly associated with early apoptosis. Fluorescent conjugates therefore support flow cytometry apoptosis detection and fluorescence microscopy apoptosis detection, but the signal is best interpreted as an apoptosis-associated membrane readout rather than a complete account of cell fate.

    The distinction matters in postinfarction tissue. Phosphatidylserine exposure can accompany early apoptosis, later membrane disruption, and some nonlethal or clearance-related cell states. Consequently, an Annexin V signal can indicate that a cardiomyocyte has entered a membrane state associated with cell death without independently proving irreversible apoptosis, identifying the upstream cause, or quantifying the total burden of cell loss. The Annexin V-PE Apoptosis Kit, catalog K2281, is therefore most informative in this literature as a measurement reagent within a broader study, not as the intervention that altered ENO1 biology.

    The mechanistic question addressed by the study

    Li and colleagues asked whether persistent postinfarction inflammation was linked to a metabolic program in macrophages and whether ENO1 functioned as a controllable point in that program. Their conceptual model connected enhanced glycolytic activity with lactate accumulation, suppression of the reparative transcription factor KLF4, inflammatory macrophage behavior, and secondary cardiac injury. The intervention was an acid-responsive nanocarrier carrying siRNA directed against ENO1. In the reported model, this intervention reduced infarct size and fibrosis, improved ventricular function, and decreased cardiomyocyte apoptosis. source A

    The proposed sequence is important for interpreting the apoptosis result. ENO1 was not presented simply as a death protein in cardiomyocytes. Instead, the study placed ENO1 primarily in macrophages, where its metabolic activity was proposed to shape the inflammatory environment. The apoptosis-associated endpoint was downstream of that macrophage-centered mechanism. A lower Annexin V signal or lower reported cardiomyocyte apoptosis could therefore be consistent with reduced inflammatory injury without demonstrating that ENO1 was directly silenced in cardiomyocytes.

    What observations support the ENO1–lactate–KLF4 model?

    The evidence combined several levels of analysis. Murine macrophage transcriptomic data showed increased glycolysis-related activity during the early inflammatory phase after infarction. Network analysis identified ENO1 among prominent glycolytic candidates. Human single-cell data then showed higher ENO1 expression in macrophage populations from infarcted hearts than in donor-heart comparators. The reported human comparison reached statistical significance at approximately P = 0.005, reported as P = 0.00485 in the text. These cross-species observations strengthen biological plausibility, although they remain primarily associative at this stage. source A

    Histological observations further placed ENO1-positive macrophages within the changing infarct environment. The reported tissue quantification used five samples, while the cell-culture validation used three biological replicates. In inflammatory-stimulation experiments, ENO1 expression increased and an ENO1 inhibitor reduced expression of inflammatory markers including Il-1β, Tnf-α, and Nos2. Those results support a relationship between ENO1 activity and inflammatory programming, but pharmacological perturbation can affect pathways beyond the intended target; the cellular result is therefore stronger when considered together with the genetic intervention and metabolic measurements rather than in isolation. source A

    The proposed metabolic bridge was lactate. The authors reported that ENO1 silencing reduced glycolytic flux and lactate accumulation, with recovery of KLF4-associated reparative signaling. Rescue experiments and protein-interaction analyses were interpreted as evidence that ENO1 did not need to bind KLF4 directly: lactate was proposed as the intermediate connecting metabolism to transcriptional state. This is a more specific explanation than simply labeling ENO1 as a marker of inflammatory macrophages, although the extent to which lactate accounts for all downstream effects remains unresolved. source A

    Which findings are strongest, and which are downstream?

    Reported comparison What it showed How it should be interpreted
    Infarcted versus sham or donor-associated macrophage populations ENO1 expression and glycolysis-related signatures were higher in postinfarction macrophages; the human expression comparison was statistically significant. Supports disease relevance and cross-species concordance, but does not by itself establish that ENO1 causes adverse remodeling.
    Inflammatory macrophage stimulation with or without ENO1 perturbation Inflammatory marker expression was reduced after ENO1 inhibition in experiments with three biological replicates. Supports a cell-intrinsic connection between ENO1 activity and inflammatory programming, while leaving room for inhibitor-specific effects.
    ENO1-silencing treatment versus control treatment in infarcted animals The intervention was associated with lower infarct and fibrosis measures, improved ventricular function, and reduced cardiomyocyte apoptosis. Provides integrated preclinical evidence that the pathway can influence repair-related outcomes; it does not assign the whole benefit to the apoptosis readout.
    Annexin V-based apoptosis-associated measurement Annexin V binding addresses cell-surface phosphatidylserine exposure within the reported assessment of cardiomyocyte apoptosis. Useful as a downstream indicator of altered cell state, but insufficient alone to distinguish fewer apoptotic cells from altered membrane exposure or clearance.

    The strongest causal claim is therefore not that Annexin V fluorescence proves ENO1-dependent cardiomyocyte apoptosis. Rather, the intervention, metabolic measurements, macrophage phenotype data, KLF4-related observations, and cardiac outcomes form a convergent preclinical model. The apoptosis-associated measurement contributes to that model by showing a tissue-level consequence compatible with less cellular injury. It does not independently identify the molecular route.

    What comparisons remain difficult to interpret?

    Several comparisons have different evidentiary meanings. Donor-versus-infarcted human tissue provides clinical relevance but is observational. Murine infarction experiments allow intervention and outcome comparison but may not reproduce the cellular composition, inflammatory timing, or comorbidities of human disease. Cultured bone-marrow-derived macrophages offer mechanistic control but simplify the myocardial environment and do not capture interactions among resident macrophages, recruited monocytes, cardiomyocytes, fibroblasts, and extracellular matrix.

    The macrophage classification also deserves caution. The study separated inflammatory and reparative populations using marker patterns that included inflammatory markers such as IL-1β and CXCL10 and reparative markers such as SPP1 and TREM2. Such categories are useful for organizing single-cell data, but macrophage states after infarction are continuous and context-dependent. A shift in marker expression should not automatically be equated with a complete change in cellular function.

    For the apoptosis endpoint specifically, reduced phosphatidylserine exposure could reflect several biologically distinct processes: fewer cells entering apoptosis, faster removal of dying cells by phagocytes, altered progression from early apoptosis to membrane rupture, or a change in the number and state of cardiomyocytes present in the sampled tissue. The study’s broader outcome pattern favors a protective interpretation, but Annexin V binding alone cannot choose among these explanations. The direction of the cardiac findings is reported, whereas the comparative magnitude and uncertainty of each endpoint are not represented in the evidence summarized here.

    Why the evidence does not yet settle translation

    The study’s human component supports relevance of ENO1 expression, not efficacy of ENO1 silencing in patients. The therapeutic findings arose from animal models, and the carrier’s infarct-responsive behavior introduces a second causal layer: outcomes may reflect the delivered siRNA, the carrier’s biodistribution and uptake, the biological effects of macrophage targeting, or interactions among these factors. A treatment-associated reduction in cardiomyocyte apoptosis consequently cannot be treated as a selective readout of one molecular event unless the relevant controls and orthogonal measurements support that attribution.

    There is also a temporal question. Macrophage metabolism, phosphatidylserine exposure, phagocytic clearance, fibrosis, and ventricular remodeling do not occur on a single biological timescale. A measurement made at one stage of infarct repair may capture the balance between injury and clearance rather than the cumulative number of cells that underwent apoptosis. This makes the Annexin V result valuable for locating a cellular consequence within the model, but insufficient for reconstructing the entire trajectory of postinfarction cell death.

    Bounded conclusion

    The published evidence supports a coherent preclinical interpretation: ENO1-associated metabolic remodeling in infarct macrophages was linked to lactate, KLF4-related reparative programming, inflammation, and adverse cardiac remodeling, while ENO1-directed intervention improved several downstream outcomes. Annexin V-based phosphatidylserine detection is relevant to the apoptosis assessment, but it measures a membrane state and should not be promoted to a standalone proof of mechanism or therapeutic success. Product documentation establishes the intended measurement principle of the cataloged reagent; the study establishes only its role and meaning within that specific experimental context, not universal assay performance, clinical efficacy, or equivalence across tissues and models.

    Publication: Targeting the ENO1 metabolic checkpoint via microenvironment-responsive nanotherapeutics promotes postinfarction cardiac repair.